MET and familial pancreatic carcinoma: The aims of this study were (i) to assess the effects of adjuvant treatment (HGF/c-Met inhibition, with or without gemcitabine) on disease progression and on circulating cells (tumour cells and PSCs) in a post-resectional orthotopic model of pancreatic cancer and (ii) to use single-cell RNA-sequencing (scRNA-seq) to characterise circulating PSCs in the metastatic setting of an unresected model of pancreatic cancer.